Becotatug Vedotin
Sponsors
Kai Hu, West China Hospital, Fudan University, First Affiliated Hospital of Guangxi Medical University, Ming-Yuan Chen
Conditions
Adjuvant TherapyCutaneous Squamous Cell Carcinoma (CSCC)Head and Neck Squamous Cell CarcinomaLocoregionally Advanced Nasopharyngeal CarcinomaNasopharyngeal Cancinoma (NPC)Nasopharyngeal Carcinoma (NPC)Oligo-metastatic CancerRAS Wild Type mCRC
Phase 2
Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
Not yet recruitingNCT07303283
Start: 2026-04-15End: 2033-04-15Target: 218Updated: 2026-03-05
A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Not yet recruitingNCT07381075
Start: 2026-02-01End: 2029-06-01Target: 120Updated: 2026-02-02
Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma
Not yet recruitingNCT07394244
Start: 2026-01-09End: 2028-12-31Target: 38Updated: 2026-02-06
Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer
Not yet recruitingNCT07490119
Start: 2026-06-01End: 2029-06-01Target: 31Updated: 2026-03-24
Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy
RecruitingNCT07496190
Start: 2026-03-01End: 2034-03-01Target: 59Updated: 2026-04-01
Phase 3
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
RecruitingNCT07459296
Start: 2026-03-05End: 2032-04-01Target: 266Updated: 2026-03-16
Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases
RecruitingNCT07481799
Start: 2026-02-06End: 2030-02-28Target: 200Updated: 2026-04-02